Phio Pharmaceuticals (PHIO) FCF Margin (2012 - 2019)
Phio Pharmaceuticals' (PHIO) quarterly FCF Margin came in at 10357.14% in Q1 2019, down 206584.0% YoY from N/an in Q1 2018, and down 194.15% on a QoQ basis from 3521.05% in Q3 2018.
Phio Pharmaceuticals (PHIO) FCF Margin (2012 - 2019) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 8 years of FCF Margin data on file, last reported at 10357.14% in Q1 2019.
- Quarterly FCF Margin fell 206584.0% year-over-year to 10357.14% in Q1 2019, while the trailing twelve-month figure through Dec 2019 was 41323.81% (down 3587091.0% YoY) and the FY2019 annual result came in at 41323.81%, down 3587091.0% from the prior year.
- FCF Margin retreated to 10357.14% in Q1 2019, from 3521.05% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 3206.9% in Q2 2018 to a low of 29250.0% in Q1 2016.
- A 5-year average of 11973.74% and a median of 9324.22% in 2018 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2015 — FCF Margin surged 238337 bps — and 2016, when it tumbled 2342647 bps.
- Tracing PHIO's FCF Margin over 5 years: stood at 5823.53% in 2015, then slumped by 255 bps to 20666.67% in 2016, then advanced by 29 bps to 14673.33% in 2017, then surged by 76 bps to 3521.05% in 2018, then slumped by 194 bps to 10357.14% in 2019.
- The last three FCF Margin figures came in at 10357.14% (Q1 2019), 3521.05% (Q3 2018), and 3206.9% (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -10,357.14% |
| Sep 30, 2018 | -3,521.05% |
| Jun 30, 2018 | -3,206.90% |
| Mar 31, 2018 | -8,291.30% |
| Dec 31, 2017 | -14,673.33% |
| Jun 30, 2016 | -20,666.67% |
| Mar 31, 2016 | -29,250.00% |
| Mar 31, 2015 | -5,823.53% |
| Dec 31, 2014 | -11,457.14% |
| Sep 30, 2014 | -11,131.25% |
| Jun 30, 2014 | -16,808.33% |
| Mar 31, 2014 | -8,206.90% |
| Dec 31, 2013 | -5,068.97% |
| Sep 30, 2013 | -1,883.70% |
| Jun 30, 2013 | -913.78% |
| Mar 31, 2013 | -2,128.30% |
| Dec 31, 2012 | -2,890.00% |
| Sep 30, 2012 | -2,210.53% |